Table 4.

Relationship between Pol η Expression and Cellular Sensitivity to Gemcitabine/Cisplatin Treatments

LC50 (with 1 nmol/L gemcitabine)GM637XP-V EGFP-pol ηXP30RO
Cisplatin (nmol/L)993 ± 23 (849 ± 61)310 ± 6 (223 ± 27)132 ± 4 (100 ± 2)
  • NOTE: Numbers in parentheses are mean ± SD from two independent experiments each conducted in duplicates of trypan blue exclusion assay.